Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).

Milestone Pharmaceuticals Inc. Common Shares

Thank you for your interest in Milestone Pharmaceuticals. While we encourage you to explore opportunities with our company, we urge you to be cautious and wary of recruitment scams in which fraudsters pose as representatives of Milestone Pharma. All current openings are available to view on our Careers page. https://milestonepharmaceuticals.applytojob.com/

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing the investigational new drug etripamil for the treatment of cardiovascular indications. Etripamil is a novel, potent and short-acting calcium channel blocker designed by Milestone and being developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of PSVT as they occur. Milestone is actively recruiting patients for a Phase 3 clinical trial of etripamil for the treatment of PSVT. Milestone plans to initiate a Phase 2 clinical trial in atrial fibrillation, another rapid heart rate condition, and expects to subsequently initiate an additional Phase 2 clinical trial in angina to establish proof-of-concept for the broader use of etripamil.

RTW Investments

Amplitude Venture Capital

Tekla Capital Management

BDC Capital Corporation

Boxer Capital

Novo Holdings

GO CAPITAL

Pappas Capital

Domain Associates

Fonds de solidarité FTQ

Forbion Capital Partners

Milestone Pharmaceuticals, Inc.

Today, there is a critical need for an innovative, novel treatment solution to support patients experiencing debilitating heart conditions.
 
Recently, we had the opportunity to join the #cardiovascular community in Washington D.C. to discuss the latest clinical trials to advance treatments for these conditions at the Global CVCT - Cardiovascular Clinical Trialists Forum. From our clinical development program, we shared the latest results on our lead investigational product, etripamil, for PSVT and AFib-RVR.
 
The results from our Phase 3 RAPID study for PSVT and our Phase 2 ReVeRA study for AFib-RVR demonstrate our commitment to help alleviate the provider burden in diagnosing and treating these debilitating and life-altering cardiovascular conditions and help patients actively self-manage their condition outside the healthcare setting.
 
You can learn more about our clinical development program here: https://bit.ly/47Dzq6m
 
#CVCT2023 #ClinicalTrials #ClinicalResearch

#DYK that the prevalence of atrial fibrillation (AFib) is expected to grow to approximately 10 million by 2025 and up to about 12 million by 2030, according to the American Heart Association? 
 
Recently at the American Heart Association Scientific Sessions 2023, we presented positive results from our ReVeRA Phase 2 clinical trial evaluating etripamil in AFib with rapid ventricular rate (AFib-RVR), a serious condition which presents in a subset of AFib patients, and is characterized by more severe episodic symptoms including heart palpitations, shortness of breath, dizziness, and/or weakness. 
 
One of the study investigators, Dr. James Ip from Weill Cornell Medicine, sat down with HCPLive to discuss the unmet needs for patients with AFib-RVR and the potential of etripamil nasal spray. 
 
Read more about the results from the study here: https://lnkd.in/ewrfDT8e
 
You can tune into Dr. Ip’s interview below. 
 
#AHA23 #AFib

Attending the Global CVCT - Cardiovascular Clinical Trialists Forum in Washington D.C. this weekend?
 
We look forward to sharing data on the efficacy and safety of etripamil, an investigational new drug, from our clinical trials to treat patients with paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation with rapid ventricular response (AFib-RVR). 
 
Let us know if you plan to attend in the comments. Members of our leadership team, including David Bharucha, MD, PhD and Anita Holz, MSN, CRNP, will be in attendance. We look forward to seeing you there! 
 
#CVCT2023 #ClinicalTrials #ClinicalResearch

Today, we reported our financial results for the Third Quarter 2023. Learn more about these results and progress in our clinical development program here: https://lnkd.in/e7hrGyfc

Tomorrow is the last day of #AHA23! Stop by our booth (#2911/B2659) today and tomorrow to learn more about the newly presented results from our ReVeRA Phase 2 clinical study of etripamil in patients with atrial fibrillation with rapid ventricular rate (AFib-RVR). We look forward to discussing how we are addressing the unmet need for patients living with AFib-RVR and paroxysmal supraventricular tachycardia (PSVT).  
  
You can learn more about the results of the study, simultaneously published in Circulation: Arrhythmia and Electrophysiology here: https://lnkd.in/ewrfDT8e
 
#Milestone #AFib #SVTAwareness

As part of a Featured Scientific Session at the @American Heart Association, today, we presented positive results from our ReVeRA Phase 2 clinical study of etripamil in AFib-RVR. The results were also simultaneously published in Circulation: Arrhythmia and Electrophysiology.
 
Patients with AFib-RVR continue to face a significant unmet need and our market research data suggests 30-40 percent of patients with AFib experience one or more symptomatic episodes of AFib-RVR requiring treatment. 
 
At Milestone, we are committed to helping improve the lives of people living with cardiovascular conditions. We plan to share an update on the continued development of self-administered etripamil nasal spray for AFib-RVR in the coming weeks.
 
You can learn more about the results here:

https://lnkd.in/ewrfDT8e
 
#Milestone #AFib #AHA23

Attending American Heart Association Scientific Sessions in Philadelphia from November 11-13?
 
Our team will be on the ground and looks forward to connecting and learning more about the latest advancements in #hearthealth. Come stop by our booth #2911/B2659 to learn more about the latest updates in #PSVT and #AFib and how we are working to address current unmet needs for patients. 
 
We look forward to seeing you there! 
 
#AHA23 #SVTAwareness

Join the Milestone Pharmaceuticals team the morning of Saturday, November 11 for a MedscapeLIVE Event where we will dive into paroxysmal supraventricular tachycardia (PSVT). 
 
PSVT is a life-altering disease affecting 1 in 300 patients and is characterized by spontaneous episodes of ventricular contractions exceeding rates of 100 beats per minute. During this symposium, experts will discuss hot topics on PSVT including clinical burden of disease, guideline recommendations, and current as well as emerging treatment strategies for PSVT. #AHA #HeartHealth #PSVT #SVTAwareness

We look forward to having you join us, and you can register here:

	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-8.09M -	-23.18M 186.73%	-55.23M 138.21%	-49.97M 9.53%	-42.85M 14.24%	-58.39M 36.25%	-59.69M 2.22%
depreciation and amortization	8K -	10K 25%	38K 280%	97K 155.26%	93K 4.12%	89K 4.30%	92K 3.37%
deferred income tax			-1.63M -	-5.53M 238.43%	-7.27M 31.45%
stock based compensation	190K -	633K 233.16%	1.19M 88.15%	4.95M 315.20%	7.28M 47.20%	9.05M 24.30%	9.53M 5.37%
change in working capital	-164K -	1.50M 1,012.20%	2.85M 90.37%	-5.81M 303.90%	2.26M 138.87%	-3.26M 244.53%	1.04M 131.76%
accounts receivables			-169K -	-112K 33.73%	465K 515.18%	-730K 256.99%
inventory			169K -	112K 33.73%	-465K 515.18%	730K 256.99%
accounts payables	-222K -	2.88M 1,395.50%	3.52M 22.39%	-2.08M 159.18%	637K 130.58%	-907K 242.39%	1.04M 214.22%
other working capital	58K -	-1.38M 2,479.31%	-672K 51.30%	-3.72M 454.17%	1.62M 143.50%	-2.35M 245.37%	-1.04M 56.01%
other non cash items			1.63M -	5.53M 238.43%	7.27M 31.45%	44K 99.39%	3.63M 8,161.36%
net cash provided by operating activities	-8.05M -	-21.05M 161.38%	-51.15M 143.05%	-50.73M 0.82%	-33.22M 34.51%	-52.47M 57.92%	-46.42M 11.52%
investments in property plant and equipment	-36K -	-5K 86.11%	-413K 8,160.00%			-272K -
acquisitions net			35.41M -			86.12M -
purchases of investments	-16.03M -	-3.03M 81.11%	-35M 1,055.50%	-90M 157.14%	-15M 83.33%	-85.85M 472.35%
sales maturities of investments	45K -	19.03M 42,193.33%	35.03M 84.05%	20M 42.90%	85M 325%	29M 65.88%	142M 389.66%
other investing activites			-35.41M -			-86.12M -	-137.24M 59.36%
net cash used for investing activites	-16.02M -	16.00M 199.84%	-384K 102.40%	-70M 18,129.17%	70M 200%	-57.12M 181.61%	4.76M 108.33%
debt repayment
common stock issued			85.36M -	24.92M 70.81%	5.05M 79.71%	2.63M 47.97%
common stock repurchased
dividends paid
other financing activites	30.72M -	80.11M 160.77%	44K 99.95%	48.31M 109,688.64%		458K -	47.79M 10,334.93%
net cash used provided by financing activities	30.72M -	80.11M 160.77%	85.41M 6.61%	73.22M 14.26%	5.05M 93.10%	3.09M 38.91%	47.79M 1,447.67%
effect of forex changes on cash
net change in cash	6.65M -	75.07M 1,029.34%	33.87M 54.88%	-47.51M 240.26%	41.83M 188.05%	-106.50M 354.61%	6.12M 105.75%
cash at beginning of period	4.23M -	10.88M 157.03%	85.95M 689.95%	119.82M 39.41%	72.31M 39.65%	114.14M 57.85%	7.64M 93.31%
cash at end of period	10.88M -	85.95M 689.95%	119.82M 39.41%	72.31M 39.65%	114.14M 57.85%	7.64M 93.31%	13.76M 80.20%
operating cash flow	-8.05M -	-21.05M 161.38%	-51.15M 143.05%	-50.73M 0.82%	-33.22M 34.51%	-52.47M 57.92%	-46.42M 11.52%
capital expenditure	-36K -	-5K 86.11%	-413K 8,160.00%			-272K -
free cash flow	-8.09M -	-21.05M 160.27%	-51.56M 144.95%	-50.73M 1.62%	-33.22M 34.51%	-52.74M 58.74%	-46.42M 11.98%

COM:MILESTONEPHARMA

Milestone Pharmaceuticals, Inc.

Last Close

1.85

22/11 21:00

Market Cap

98.12M

Beta: -

Volume Today

276.50K

Avg: -

Preview